M&A is back on the menu, but there are still reasons to be cautious.
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.